Boost Biomes Competitors

Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need.

Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ .

We are accelerating the world's transformation to sustainable materials, by replacing fossil fuel sources with plants. We believe that all products should be responsibly sourced, traceable, and transparent — the sustainable source™. At Geno, we are breaking the planet's reliance on these fossil fuels by creating something better. Our vision to drive climate action at scale starts by making the same molecules, ingredients, and materials we rely on every day, but deriving them from more sustainable sources. Spanning products across a wide variety of industries, Geno’s technologies power high-performance at leading scale and volume, delivering plant-derived ingredients to some of the world’s largest brands. And with that we are shaping the creation of more transparent, traceable, and responsible global supply chains for brands and their consumers to rely on. Our technology and capabilities, developed and honed over two decades, harness the ever-increasing power of biotechnology, where microorganisms and industrial processes are designed to ferment plant sugars into materials and ingredients. Geno's Innovation Center is home to our world-class research and development team of engineers and scientists who have deployed more than $300 million in technology investment, collaborating to create a portfolio of 2,200 patents and applications. The IP covers product pathways, synthetic biology approaches to engineering microorganisms, processes to bio-manufacture products, their sometimes unique biological compositions, and product applications. We work closely with some of the world’s leading brands to develop solutions that align superior performance and economics with sustainability. We also produce and market our own branded products and license our geno technology to some of the world’s largest manufacturers including Novamont, Qore® (a joint venture of Cargill and HELM), Covestro, and Aquafil. Feeling like you’d be a fit? Join us: http://www.genomatica.com/careers/